Although there is no known clinically meaningful cutoff between CD30 “positive” and “negative” IHC values, and BV was approved in CD30-expressing MF and non-ALCL PTCL without a specific CD30 threshold, clinicians are requesting CD30 percentages on IHC tests to satisfy payors, who require the information.38 When clinically appropriate, more than one biopsy may be assessed and tested for a more complete picture of CD30 levels within each patient’s disease. The gene discussed is TNFRSF8; the disease is mature T-cell and NK-cell non-Hodgkin lymphoma.